Quiet on the insider front: nobody at Repare Therapeutics Inc. bought or sold RPTX shares on the open market this past year.
No open-market insider buying or selling in the last full quarter. Insiders bought in 0 of the last 7 full quarters.
Quiet on the insider front: nobody at Repare Therapeutics Inc. bought or sold RPTX shares on the open market this past year.
No open-market insider buying or selling in the last full quarter. Insiders bought in 0 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Mar 14, 2025 | Koehler Maria | Executive Officer | Sell | 3,596 | $1.14 | $4K | SEC |
| Mar 14, 2025 | Zinda Michael | Executive Officer | Sell | 5,611 | $1.14 | $6K | SEC |
| Mar 14, 2025 | Forte Steve | CFO | Sell | 6,884 | $1.14 | $8K | SEC |
| Mar 14, 2025 | Segal Lloyd Mitchell | CEO | Sell | 21,179 | $1.14 | $24K | SEC |
| Apr 1, 2024 | Segal Lloyd Mitchell | CEO | Sell | 2,650 | $4.62 | $12K | SEC |
| Apr 1, 2024 | Segal Lloyd Mitchell | CEO | Sell | 2,491 | $4.63 | $12K | SEC |
| Apr 1, 2024 | Forte Steve | CFO | Sell | 825 | $4.62 | $4K | SEC |
| Apr 1, 2024 | Forte Steve | CFO | Sell | 789 | $4.61 | $4K | SEC |
| Apr 1, 2024 | Zinda Michael | Executive Officer | Sell | 410 | $4.66 | $2K | SEC |
| Apr 1, 2024 | Zinda Michael | Executive Officer | Sell | 450 | $4.64 | $2K | SEC |
| Apr 1, 2024 | Koehler Maria | Executive Officer | Sell | 300 | $4.66 | $1K | SEC |
| Apr 1, 2024 | Koehler Maria | Executive Officer | Sell | 500 | $4.64 | $2K | SEC |
| Mar 27, 2024 | Zinda Michael | Executive Officer | Sell | 450 | $4.61 | $2K | SEC |
| Mar 27, 2024 | Koehler Maria | Executive Officer | Sell | 500 | $4.78 | $2K | SEC |
| Mar 27, 2024 | Segal Lloyd Mitchell | CEO | Sell | 2,650 | $4.63 | $12K | SEC |
There were no open-market insider trades in RPTX in the last 12 months. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
No congressional trades in RPTX were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).